Ovarian PRP for Diminished Ovarian Reserve
Generation Next Fertility · with Igenomix · NCT05790655
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 35–42 · Women only
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 230
- US sites recruiting
- 1
- Study start
- October 7, 2023
- Record last updated
- February 13, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This prospective double-blinded randomized placebo control study aims to determine if In Vitro Fertilization (IVF) outcomes are improved by ovarian platelet-rich plasma injections (oPRP) for women diagnosed with diminished ovarian reserve (DOR). Women with DOR notoriously have the lowest chance of pregnancy and live birth compared to age-matched peers with a normal or robust ovarian reserve.
Being studied: oPRP; Placebo- Serum
Conditions: Diminished Ovarian Reserve
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Clinical diagnosis of diminished ovarian reserve
- Clinical diagnosis of poor ovarian response
- Women age 35-42
Exclusion Criteria
- Clinical diagnosis of premature ovarian failure
- Clinical diagnosis of menopause.
- Under 35 years of age
- Over 42 years of age
Recruiting US locations
Generation Next Fertility
New York, NY 10022
Site contact: Jesse Hade, MD · 212-641-0906 · j.hade@generationnextfertility.com
Study contacts (from the official record)
- Alicia Broussard, PhD · 3174456958 · a.broussard@generationnextfertility.com
- Jesse Hade, MD · 2126410906 · j.hade@generationnextfertility.com
Similar studies in New York
All healthy volunteers studies in New York →- RecruitingHealthy volunteers
Using Middle School Science Teachers to Address Cancer Health Disparities
Weill Medical College of Cornell University
- Location
- New York, NY + 1 other US site
- Eligibility basics
- Ages 10+
- RecruitingHealthy volunteersPhase 1/Phase 2
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Novartis Pharmaceuticals
- Location
- New York, NY + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Staten Island, NY + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
Merck Sharp & Dohme LLC
- Location
- East Syracuse, NY + 14 other US sites
- Eligibility basics
- Ages 2 mo–1